Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Marinus (MRNS)
NASDAQ:MRNS
Holding MRNS?
Track your performance easily
MRNS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.05 - $11.26
Previous Close$1.55
Volume228.14K
Average Volume (3M)660.70K
Market Cap
$85.38M
Enterprise Value$77.31M
Total Cash (Recent Filing)$64.70M
Total Debt (Recent Filing)$56.63M
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Nov 05, 2024EPS Estimate
-$0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.66
Shares Outstanding55,084,038
10 Day Avg. Volume466,198
30 Day Avg. Volume660,704
Standard Deviation0.26
R-Squared0.05
Alpha0.00772
Financial Highlights & Ratios
Price to Book (P/B)-1.80
Price to Sales (P/S)2.82
Price to Cash Flow (P/CF)-0.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.55
Enterprise Value/Gross Profit2.66
Enterprise Value/Ebitda-0.57
Forecast
1Y Price Target
$5.60Price Target Upside270.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
Marinus News
PremiumPre-Earnings
Is MRNS a Buy, Before Earnings?
Bulls Say, Bears Say
Bulls Say
Global ExpansionThe global footprint for Ztalmy in CDKL5 Deficiency Disorder (CDD) has expanded with activation of managed access programs in MENA, Russia, and Canada and expected upcoming launches in Europe and China.
Stock ValuationThe stock trades near cash levels, suggesting a risk/reward skewed to the upside ahead of the data readout.
Trial Design And ExecutionThe trial design has been adjusted to increase the chance of success by lowering somnolence rates and controlling the placebo response.
Bears Say
Clinical TrialsThe trial is enrolling more severely affected patients, which could pose an added risk.
Commercial OutlookThe long time frame to the initiation of treatment and the lack of overall urgency could limit the commercial opportunity.
Regulatory ChallengesThe lack of benefit on progression to IV anesthesia suggests a tough regulatory path and unclear commercial success.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
MRNS FAQ
What was Marinus’s price range in the past 12 months?
Marinus lowest stock price was $1.05 and its highest was $11.26 in the past 12 months.
What is Marinus’s market cap?
Currently, no data Available
When is Marinus’s upcoming earnings report date?
Marinus’s upcoming earnings report date is Nov 05, 2024 which is in 47 days.
How were Marinus’s earnings last quarter?
Marinus released its earnings results on Aug 13, 2024. The company reported -$0.63 earnings per share for the quarter, missing the consensus estimate of -$0.59 by -$0.04.
Is Marinus overvalued?
According to Wall Street analysts Marinus’s price is currently Undervalued.
Does Marinus pay dividends?
Marinus does not currently pay dividends.
What is Marinus’s EPS estimate?
Marinus’s EPS estimate is -$0.43.
How many shares outstanding does Marinus have?
Marinus has 55,084,038 shares outstanding.
What happened to Marinus’s price movement after its last earnings report?
Marinus reported an EPS of -$0.63 in its last earnings report, missing expectations of -$0.59. Following the earnings report the stock price went down -4.065%.
Which hedge fund is a major shareholder of Marinus?
Among the largest hedge funds holding Marinus’s share is Woodline Partners LP. It holds Marinus’s shares valued at 5M.
---
Marinus Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.60 (270.86% Upside)
$5.60 (270.86% Upside)
Blogger Sentiment
Bullish
MRNS Sentiment 66%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 1.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 3.8%
Last 30 Days ▼ 3.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-74.59%
12-Months-Change
Fundamentals
Return on Equity
-2986.55%
Trailing 12-Months
Asset Growth
-56.72%
Trailing 12-Months
Company Description
Marinus
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded by Geoffrey E. Chaiken, Harry H. Penner Jr., Vincent A. Pieribone and Kenneth R. Shaw on August 14, 2003 and is headquartered in Radnor, PA.
---
MRNS Earnings Call
Q2 2024
0:00 / 0:00
---
MRNS Stock 12 Month Forecast
Average Price Target
$5.60
▲(270.86% Upside)
Technical Analysis
Best Analysts Covering MRNS
1 Year
1 Year Success Rate
12/25 ratings generated profit
1 Year Average Return
-8.34%
reiterated a buy rating 9 days ago
Copying Marc Goodman's trades and holding each position for 1 Year would result in 48.00% of your transactions generating a profit, with an average return of -8.34% per trade.
---